Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | ACVR1 | Q04771 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | AKR1C3 | P42330 | 3/20 | 0.39 |
| ▸ | CASP6 | P55212 | 1/20 | 0.38 |
| ▸ | GFER | P55789 | 1/20 | 0.38 |
| ▸ | LPL | P06858 | 2/20 | 0.38 |
| ▸ | LIPG | Q9Y5X9 | 2/20 | 0.38 |
| ▸ | SYK | P43405 | 1/20 | 0.37 |
| ▸ | P4HB | P07237 | 1/20 | 0.37 |
| ▸ | HTT | P42858 | 1/20 | 0.37 |
| ▸ | NPC1 | O15118 | 1/20 | 0.37 |
| ▸ | RAB9A | P51151 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL578443 | 0.85 | LIPG (0.44) | KMT2AMEN1AKR1C3CASP6GFER | |
| SCHEMBL2379423 | 0.85 | GFER (0.55) | MAPTKMT2AMEN1CASP6GFER | |
| SCHEMBL24511506 | 0.84 | LPL (0.42) | KMT2AMEN1AKR1C3CASP6GFER | |
| SCHEMBL31646023 | 0.82 | KDM4E (0.40) | HRH3KMT2AMEN1AKR1C3NPC1 | |
| SCHEMBL15656543 | 0.82 | MAPT (0.48) | MAPTKMT2AMEN1HTT | |
| SCHEMBL14167571 | 0.82 | AKR1C3 (0.52) | MAPTKMT2AAKR1C3HTT | |
| SCHEMBL31646075 | 0.82 | POLB (0.42) | MAPTKMT2AMEN1AKR1C3CASP6 | |
| SCHEMBL3017161 | 0.81 | GFER (0.50) | MAPTKMT2AMEN1AKR1C3CASP6 | |
| SCHEMBL15656742 | 0.81 | TDP1 (0.58) | MAPTKMT2AMEN1HTT | |
| SCHEMBL14167596 | 0.80 | PDK2 (0.45) | MAPTSYK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250230168-A1 | AZASPIRO WRN INHIBITORS | GILEAD SCIENCES, INC. | 2025-07-17 | — | — | US | disclosed |
| WO-2025137640-A1 | AZASPIRO WRN INHIBITORS | GILEAD SCIENCES, INC. (US) | 2025-06-26 | — | — | WO | disclosed |
| WO-2023198114-A1 | ALK2 KINASE INHIBITOR | 杭州邦顺制药有限公司 | 2023-10-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250230168-A1 | AZASPIRO WRN INHIBITORS | WRN, RECQL, BLM | HRH3 4680/4885MAPT 4813/4885ACVR1 2412/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.